Table 7.
Stability of antiphospholipid antibodies marker status over time in inflammatory bowel diseases patients with at least 2 samples during the disease course n (%)
| APLA marker | CD (n = 198) | UC (n = 103) |
| Anti-β2-GPI IgG | ||
| Stable negative | 194 (98.0) | 97 (94.2) |
| Stable positive | 1 (0.5) | 2 (1.9) |
| Neg. to pos. | 0 (0.0) | 3 (2.9) |
| Pos. to neg. | 3 (1.5) | 1 (1.0) |
| Anti-β2-GPI IgM | ||
| Stable negative | 186 (94.0) | 94 (91.3) |
| Stable positive | 4 (2.0) | 3 (2.9) |
| Neg. to pos. | 6 (3.0) | 5 (4.9) |
| Pos. to neg. | 2 (1.0) | 1 (0.9) |
| Anti-β2-GPI IgA | ||
| Stable negative | 190 (96.0) | 93 (90.3) |
| Stable positive | 1 (0.5) | 4 (3.9) |
| Neg. to pos. | 3 (1.5) | 5 (4.9) |
| Pos. to neg. | 4 (2.0) | 1 (0.9) |
| ACA IgG | ||
| Stable negative | 139 (70.2) | 95 (92.2) |
| Stable positive | 3 (1.5) | 1 (1.0) |
| Neg. to pos. | 42 (21.2) | 6 (5.8) |
| Pos. to neg. | 14 (7.1) | 1 (1.0) |
| ACA IgM | ||
| Stable negative | 173 (87.4) | 95 (92.2) |
| Stable positive | 3 (1.5) | 1 (1.0) |
| Neg. to pos. | 18 (9.1) | 7 (6.8) |
| Pos. to neg. | 4 (2.0) | 0 (0.0) |
| ACA IgA | ||
| Stable negative | 73 (36.9) | 78 (75.7) |
| Stable positive | 13 (6.6) | 0 (0.0) |
| Neg. to pos. | 93 (46.9) | 24 (23.3) |
| Pos. to neg. | 19 (9.6) | 1 (1.0) |
Anti-PS/PT measurements were only preformed on the first available serum samples of the patients. APLA: Antiphospholipid antibodies; β2-GPI: Beta2-glycoprotein-I; ACA: Anti-cardiolipin antibody; PS/PT: Phosphatidylserine/prothrombin complex; CD: Crohn’s disease; UC: Ulcerative colitis.